Abrocitinib: A Comprehensive Review of its Efficacy and Safety in Dermatology

Sunil Dogra; Shikha Shah; Manavi Gupta; Ayush Sharma; Seema Chhabra

doi:10.4103/idoj.idoj_449_24

Abrocitinib: A Comprehensive Review of its Efficacy and Safety in Dermatology

Indian Dermatol Online J. 2024 Oct 28;15(6):930-941. doi: 10.4103/idoj.idoj_449_24. eCollection 2024 Nov-Dec.

Authors

Sunil Dogra¹, Shikha Shah¹, Manavi Gupta¹, Ayush Sharma², Seema Chhabra²

Affiliations

¹ Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
² Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Abstract

Abrocitinib is a novel oral small molecule which acts as a selective JAK-1 inhibitor. Currently approved for use in moderate-to-severe cases of atopic dermatitis, this drug is gaining a rapid impetus for its use across various inflammatory dermatoses for its selective downstream action on cytokines of the JAK-1 pathway. Its efficacy and safety in atopic dermatitis has been established in phase 3 clinical trials. The future implication of this drug will depend largely on feasibility and practical use in Indian scenario.

Keywords: Abrocitinib; JAK-STAT inhibitor; Janus Kinase; oral small molecule.

Publication types

Review